Covance, Inc. a division of LabCorp® Company Profile

Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, employees in more than 60 countries, and more than 15,000 employees worldwide.

NONCLINICAL DEVELOPMENT
(Toxicology, Research Products, Analytical Services)
Covance Early Development supported 82% of the drugs approved by the FDA in 2016:
- 13 global facilities with 3,800+ staff
- 600+ clients served per year
- ~12,000 studies conducted per year
- 300+ IND-CTA-enabling programs delivered in past 5 years

CLINICAL DEVELOPMENT
(Clinical Pharmacology, Clinical, Central Labs)
-Supported 50% of latest breakthrough cancer treatments
-Supported development of the top 25 currently marketed medicines
-70% of clinical programs on or ahead of enrollment timelines
-Broad-based, scalable and market-leading,
-Biomarker capability
->99% of samples received within stability
In the last 5 years (2011-2015), we participated in >4400 studies, >240M tests, >90 countries, >1.3M patients, >140k patients. Note, these are all Covance only; LCT numbers not yet folded in, so eventual numbers will be higher when final 2012-2016 numbers are posted in a month or two.
-Five Clinical Pharmacology units with over 350 beds

PERIAPPROVAL & MARKET ACCESS
-Results-driven reimbursement support for >60% of the biologics market
-Designed and managed world’s largest safety registry ever – iPledge
-Team of experts dedicated to risk management and Pharmacovigilance
-Bi-coastal call center capabilities to deliver patient and physician support